GB0724860D0 - Screening - Google Patents

Screening

Info

Publication number
GB0724860D0
GB0724860D0 GBGB0724860.2A GB0724860A GB0724860D0 GB 0724860 D0 GB0724860 D0 GB 0724860D0 GB 0724860 A GB0724860 A GB 0724860A GB 0724860 D0 GB0724860 D0 GB 0724860D0
Authority
GB
United Kingdom
Prior art keywords
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0724860.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB0724860.2A priority Critical patent/GB0724860D0/en
Publication of GB0724860D0 publication Critical patent/GB0724860D0/en
Priority to EP08865061.9A priority patent/EP2235533B1/en
Priority to GB1000386.1A priority patent/GB2468006C/en
Priority to US12/809,181 priority patent/US8790933B2/en
Priority to EP12192130.8A priority patent/EP2573563B1/en
Priority to PCT/GB2008/004223 priority patent/WO2009081136A2/en
Priority to JP2010538902A priority patent/JP5763343B2/ja
Priority to AU2008339595A priority patent/AU2008339595C1/en
Priority to CA2710145A priority patent/CA2710145C/en
Priority to ES12192130T priority patent/ES3006458T3/es
Priority to US14/255,939 priority patent/US9260505B2/en
Priority to JP2015117562A priority patent/JP6425620B2/ja
Priority to US14/989,744 priority patent/US10126313B2/en
Priority to US16/151,991 priority patent/US20190094247A1/en
Priority to US17/107,617 priority patent/US20210148939A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB0724860.2A 2007-12-20 2007-12-20 Screening Ceased GB0724860D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0724860.2A GB0724860D0 (en) 2007-12-20 2007-12-20 Screening
ES12192130T ES3006458T3 (en) 2007-12-20 2008-12-19 Screening
JP2010538902A JP5763343B2 (ja) 2007-12-20 2008-12-19 スクリーニング
CA2710145A CA2710145C (en) 2007-12-20 2008-12-19 Screening of conformation specific binding partners of gpcrs
US12/809,181 US8790933B2 (en) 2007-12-20 2008-12-19 Screening
EP12192130.8A EP2573563B1 (en) 2007-12-20 2008-12-19 Screening
PCT/GB2008/004223 WO2009081136A2 (en) 2007-12-20 2008-12-19 Screening
EP08865061.9A EP2235533B1 (en) 2007-12-20 2008-12-19 Screening
AU2008339595A AU2008339595C1 (en) 2007-12-20 2008-12-19 Screening
GB1000386.1A GB2468006C (en) 2007-12-20 2008-12-19 Screening
US14/255,939 US9260505B2 (en) 2007-12-20 2014-04-17 Methods for screening for binding partners of G-protein coupled receptors
JP2015117562A JP6425620B2 (ja) 2007-12-20 2015-06-10 スクリーニング
US14/989,744 US10126313B2 (en) 2007-12-20 2016-01-06 Methods for screening for binding partners of G-protein coupled receptors
US16/151,991 US20190094247A1 (en) 2007-12-20 2018-10-04 Methods for screening for binding partners of g-protein coupled receptors
US17/107,617 US20210148939A1 (en) 2007-12-20 2020-11-30 Methods for screening for binding partners of g-protein coupled receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0724860.2A GB0724860D0 (en) 2007-12-20 2007-12-20 Screening

Publications (1)

Publication Number Publication Date
GB0724860D0 true GB0724860D0 (en) 2008-01-30

Family

ID=39048448

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0724860.2A Ceased GB0724860D0 (en) 2007-12-20 2007-12-20 Screening
GB1000386.1A Active GB2468006C (en) 2007-12-20 2008-12-19 Screening

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1000386.1A Active GB2468006C (en) 2007-12-20 2008-12-19 Screening

Country Status (8)

Country Link
US (5) US8790933B2 (cg-RX-API-DMAC7.html)
EP (2) EP2573563B1 (cg-RX-API-DMAC7.html)
JP (2) JP5763343B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008339595C1 (cg-RX-API-DMAC7.html)
CA (1) CA2710145C (cg-RX-API-DMAC7.html)
ES (1) ES3006458T3 (cg-RX-API-DMAC7.html)
GB (2) GB0724860D0 (cg-RX-API-DMAC7.html)
WO (1) WO2009081136A2 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2456236B8 (en) * 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2483661B1 (en) 2009-09-28 2020-02-05 Koninklijke Philips N.V. Substance determining apparatus and method
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP3333185A1 (en) 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs
WO2011033322A2 (en) * 2011-01-07 2011-03-24 Heptares Therapeutics Ltd Crystal structure
KR101963914B1 (ko) 2011-02-23 2019-03-29 매사추세츠 인스티튜트 오브 테크놀로지 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법
WO2012120315A2 (en) * 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
EP2578695A1 (en) * 2011-10-05 2013-04-10 Albert-Ludwigs-Universität Freiburg Assay for Clostridium botulinum Neurotoxin
ES2676827T3 (es) 2012-06-01 2018-07-25 Heptares Therapeutics Limited Ensayos
US20150216977A1 (en) 2012-09-18 2015-08-06 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
WO2014045081A1 (en) * 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
DK2951201T3 (en) * 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
WO2014124020A1 (en) * 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
CN105593240B (zh) * 2013-06-11 2024-05-31 保罗·谢勒学院 用于以单氨基酸分辨率确定可突变配体-gpcr结合的方法以及突变配体和gpcr对
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
GB201415094D0 (en) 2014-08-26 2014-10-08 Heptares Therapeutics Ltd GPCR receptor binding domain and uses thereof
EP3839061B1 (en) 2014-10-27 2022-12-07 King Abdullah University Of Science And Technology Methods and systems for identifying ligand-protein binding sites
EP3212784B1 (en) 2014-10-31 2019-05-29 Abilita Bio, Inc. Modified membrane spanning proteins and methods for the preparation and use thereof
US20180224438A1 (en) * 2015-08-10 2018-08-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Stabilized vesicle-functionalized microparticles for chemical separations and rapid formation of polymer frits in silica capillaries using spatially-defined thermal polymerization
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
EP3452516A4 (en) 2016-05-04 2019-11-27 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10320280B2 (en) * 2016-11-08 2019-06-11 Analog Devices Global Unlimited Company LC filter including coupled inductors for reducing ripple in switching power supplies
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
FR3069644B1 (fr) * 2017-07-28 2024-07-12 Cisbio Bioassays Methode pour mesurer la modulation de l'activation d'un recepteur couple a une proteine g
AU2018358804A1 (en) * 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US11262309B2 (en) * 2018-07-11 2022-03-01 Advanced Cytometry Instrumentation Systems, Llc Methods for lipid measurement in cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CA3108892A1 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
EP3914916A1 (en) * 2019-01-22 2021-12-01 InterAx Biotech AG Beta-arrestin mutants
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020243601A1 (en) 2019-05-31 2020-12-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Synthesis of nanoscint particles
EP3953477A4 (en) 2019-06-06 2022-06-22 Inscripta, Inc. HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
WO2021064610A1 (en) * 2019-10-01 2021-04-08 Ac Immune Sa Micro-radiobinding assays for ligand screening
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
AU2020402526B2 (en) 2019-12-10 2025-01-23 Inscripta, Inc. Novel MAD nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
WO2021126886A1 (en) 2019-12-18 2021-06-24 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
CN115135370A (zh) 2020-01-27 2022-09-30 因思科瑞普特公司 电穿孔模块和仪器
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
CA3204158A1 (en) 2021-01-04 2022-07-07 Juhan Kim Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
CN114836517B (zh) * 2022-04-20 2026-03-17 合肥中科普瑞昇生物医药科技有限公司 一种A2aR拮抗剂的高通量筛选体系及其应用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
EP4689151A2 (en) * 2023-03-28 2026-02-11 Ibrahim, Yasir, H. Methods of enzyme purification using g-proteins as controllable affinity probes
EP4621788A1 (en) * 2024-03-22 2025-09-24 Genome Research Limited Gpcr
WO2026018204A1 (en) * 2024-07-18 2026-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for the quantification of plasma amyloid-beta biomarkers in alzheimer's disease
WO2026025080A1 (en) * 2024-07-26 2026-01-29 Bioventures, Llc Enable discovery of bcl-2 family inhibitors targeting mode ii complexes

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
JP3147916B2 (ja) * 1991-03-08 2001-03-19 森永製菓株式会社 体外免疫方法
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US20030036092A1 (en) * 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5585277A (en) * 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
WO1995032425A1 (en) 1994-05-23 1995-11-30 Smithkline Beecham Corporation Encoded combinatorial libraries
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
EP0906339A2 (en) 1996-03-27 1999-04-07 NG, Gordon, Y., K. Receptor and transporter antagonists
EP0910648A1 (en) * 1996-04-15 1999-04-28 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
EP1068356B8 (en) * 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
US6475733B1 (en) * 1998-04-06 2002-11-05 Lerner Pharmaceuticals, Inc. Cell surface receptors for the detection and identification of compounds
US6692696B1 (en) * 1998-06-18 2004-02-17 ARETé ASSOCIATES Biosensor
US7094593B1 (en) * 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
WO2000070343A2 (en) * 1999-05-14 2000-11-23 Repliscent, Inc. G-protein coupled receptor based biosensors and sense replication systems
IL149569A0 (en) 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
JP2003523744A (ja) * 2000-02-09 2003-08-12 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Ccr5に対する抗体
CA2403784A1 (en) * 2000-03-21 2001-09-27 Consensus Pharmaceuticals, Inc. Binding compounds and methods for identifying binding compounds
CA2402392A1 (en) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
US7678539B2 (en) * 2000-08-10 2010-03-16 Corning Incorporated Arrays of biological membranes and methods and use thereof
AU2001286945A1 (en) * 2000-08-30 2002-03-13 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6448377B1 (en) * 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
WO2002059346A2 (en) 2000-10-26 2002-08-01 New England Medical Center Hospitals, Inc. Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
US20030232331A1 (en) 2000-12-05 2003-12-18 Casman Stacie J. Novel proteins and nucleic acids encoding same
EP1379656A2 (en) 2001-02-14 2004-01-14 Amgen Inc. G-protein coupled receptor molecules and uses thereof
CN1516706A (zh) 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
JPWO2002079784A1 (ja) 2001-03-30 2004-07-22 サントリー株式会社 G蛋白質結合型レセプターの構造モデルおよび当該構造モデルを用いたg蛋白質結合型レセプターに結合するリガンドの設計方法
US20030129649A1 (en) * 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US20050009204A1 (en) * 2003-07-11 2005-01-13 Ye Fang Multiplexed binding assays for receptor arrays
DE60214869T2 (de) 2001-10-25 2007-04-12 Astex Technology Ltd., Cambridge Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung
US7115377B2 (en) * 2001-10-26 2006-10-03 Atto Bioscience, Inc. Cell-based assays for G-protein-coupled receptor-mediated activities
AU2003227268A1 (en) 2002-03-28 2003-10-13 Takeda Chemical Industries, Ltd. Novel screening method
JP2004238384A (ja) 2002-03-28 2004-08-26 Takeda Chem Ind Ltd 新規スクリーニング方法
CA2483701A1 (en) 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Constitutively active histamine h3 receptor mutants and uses thereof
EP1549318B1 (en) * 2002-05-01 2010-02-17 Vertex Pharmaceuticals Incorporated Crystal structure of aurora-2 protein and binding pockets thereof
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
US20040096914A1 (en) * 2002-11-20 2004-05-20 Ye Fang Substrates with stable surface chemistry for biological membrane arrays and methods for fabricating thereof
US7745161B2 (en) * 2003-12-19 2010-06-29 Palo Alto Research Center Incorporated Amplification of enzymatic reactions for use with an enthalpy array
US20050287519A1 (en) * 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
KR100575682B1 (ko) * 2004-05-24 2006-05-03 엘지전자 주식회사 실외기간 균압관을 구비한 공기조화기
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
WO2006007857A1 (en) * 2004-07-23 2006-01-26 Hvidovre Hospital Bilf1, a constitutive active g-protein coupled receptor
US20060188964A1 (en) 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
JP2006340717A (ja) 2005-05-11 2006-12-21 Sekisui Chem Co Ltd Gタンパク質共役型受容体に対する結合性評価方法及び評価用組成物、融合タンパク質、並びに、遺伝子
FR2890174B1 (fr) 2005-08-30 2009-04-24 Cis Bio Internat Sa Procede pour la mise en evidence d'un processus biologique par mesure d'un fret
US20070154947A1 (en) * 2005-08-31 2007-07-05 The Trustees Of Princeton University Chemical biodiscriminator
US20070196389A1 (en) * 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
WO2009051769A1 (en) 2007-10-17 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for crystallizing g protein-coupled receptors
CA2701283C (en) * 2007-10-22 2014-07-15 The Scripps Research Institute Methods and compositions for obtaining high-resolution crystals of membrane proteins
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) * 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) * 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP3333185A1 (en) * 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs
EP2611826B1 (en) 2010-08-30 2016-09-21 Confometrx, Inc. Method and composition for crystallizing a family c gpcr
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP2014516963A (ja) 2011-05-13 2014-07-17 レセプトス インコーポレイテッド Gタンパク質共役レセプターを結晶化するための新規融合パートナー
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
ES2676827T3 (es) 2012-06-01 2018-07-25 Heptares Therapeutics Limited Ensayos
US20150261911A1 (en) 2014-03-13 2015-09-17 Heptares Therapeutics Limited Crystal structure

Also Published As

Publication number Publication date
US10126313B2 (en) 2018-11-13
JP6425620B2 (ja) 2018-11-21
EP2573563B1 (en) 2024-12-25
JP2011508875A (ja) 2011-03-17
WO2009081136A3 (en) 2009-10-15
AU2008339595B2 (en) 2013-12-12
AU2008339595C1 (en) 2015-05-07
EP2235533A2 (en) 2010-10-06
JP2015200666A (ja) 2015-11-12
CA2710145C (en) 2018-06-19
WO2009081136A2 (en) 2009-07-02
US20190094247A1 (en) 2019-03-28
GB2468006B (en) 2013-05-15
US20210148939A1 (en) 2021-05-20
EP2573563C0 (en) 2024-12-25
CA2710145A1 (en) 2009-07-02
US8790933B2 (en) 2014-07-29
GB2468006C (en) 2015-06-24
ES3006458T3 (en) 2025-03-18
JP5763343B2 (ja) 2015-08-12
US20110027910A1 (en) 2011-02-03
US9260505B2 (en) 2016-02-16
EP2235533B1 (en) 2019-03-06
GB201000386D0 (en) 2010-02-24
AU2008339595A1 (en) 2009-07-02
EP2573563A1 (en) 2013-03-27
US20160327576A1 (en) 2016-11-10
US20140316116A1 (en) 2014-10-23
GB2468006A (en) 2010-08-25

Similar Documents

Publication Publication Date Title
GB2468006B (en) Screening
GB2449742B (en) Speech screening
IL202616A0 (en) Substituted imidazoheterocycles
ZA201001683B (en) Substituted piperidino-dihydrothienopyrimidines
GB0710976D0 (en) Am Screening method
GB2453029B (en) Well screens
ZA201000768B (en) Screens
IL200965A0 (en) Substituted tetrahydropyrroloquinolines
GB0711341D0 (en) Multilevel screening
GB0715306D0 (en) Screening
GB0719474D0 (en) Screens
AU3702P (en) DarwinGold Dianella ensifolia
AU3595P (en) Goldust Strobilanthes anisophyllus
AU3952P (en) FLOCHRDEF Chrysocephalum apiculatum
AU3642P (en) TAS100 Dianella tasmanica
AU3606P (en) Jaywick xTriticosecale
AU3613P (en) LS005A01 Leucospermum cuneiforme
AU3646P (en) TAS300 Dianella tasmanica
GB0712357D0 (en) Trommel
GB0710510D0 (en) Screening method
GB0709410D0 (en) Chemical screening
GB0623332D0 (en) Improved screening methods
GB0712802D0 (en) Screen
GB0706982D0 (en) Atmospheric screening
ZA201000435B (en) Substituted imidazoheterocycles

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)